Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Total Non-Current Liabilities (2020 - 2025)

Historic Total Non-Current Liabilities for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Q3 2025 value amounting to $189.3 million.

  • Tarsus Pharmaceuticals' Total Non-Current Liabilities rose 3761.92% to $189.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $189.3 million, marking a year-over-year increase of 3761.92%. This contributed to the annual value of $152.5 million for FY2024, which is 12838.29% up from last year.
  • As of Q3 2025, Tarsus Pharmaceuticals' Total Non-Current Liabilities stood at $189.3 million, which was up 3761.92% from $152.5 million recorded in Q4 2024.
  • In the past 5 years, Tarsus Pharmaceuticals' Total Non-Current Liabilities registered a high of $189.3 million during Q3 2025, and its lowest value of $10.1 million during Q1 2021.
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $37.8 million (2023), whereas its average is $61.5 million.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Total Non-Current Liabilities skyrocketed by 22444.77% in 2022, and later soared by 1881.09% in 2023.
  • Tarsus Pharmaceuticals' Total Non-Current Liabilities (Quarter) stood at $11.5 million in 2021, then surged by 203.74% to $34.9 million in 2022, then skyrocketed by 91.48% to $66.8 million in 2023, then skyrocketed by 128.38% to $152.5 million in 2024, then grew by 24.19% to $189.3 million in 2025.
  • Its last three reported values are $189.3 million in Q3 2025, $152.5 million for Q4 2024, and $137.6 million during Q3 2024.